Results 11 to 20 of about 34,903 (209)

Pharmacokinetics of Aztreonam-Avibactam After Single- and Multiple-Dose Administration: A Phase 1, Open-Label Study in Healthy Chinese Participants and Ethnic Comparison with Non-Chinese Participants. [PDF]

Clin Pharmacol Drug Dev
ABSTRACT Combined treatment with aztreonam (an established intravenous antibiotic) and avibactam (a β‐lactamase inhibitor) has the potential to address the unmet need for safe and effective agents to combat infections caused by Gram‐negative bacteria producing metallo β‐lactamases (MBLs).
Wang J, He J, Wu J, Zhang J, Ma Y, Ren X, Wei H, Zhang C, Zhu H, Raber SR, Cong S.   +10 more
europepmc   +2 more sources

Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant Escherichia coli With Tigecycline Monotherapy [PDF]

, 2020
We present a successful treatment, with tigecycline monotherapy, of acute prostatitis caused by multidrug-resistant Escherichia coli harboring an NDM-1 carbapemenase along with a CMY-2 cephalosporinase and a TEM ...
Babouee Flury, Baharak, Buetti, Niccolo, Casanova, Carlo, Furrer, Hansjakob, Jent, Philipp, Livermore, David M, Lo Priore, Elia, Pelzer, Niklas   +7 more
core   +2 more sources

Aztreonam: clinical and pharmacological characteristics at the present stage [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2023
One of the urgent problems of modern health care is the growing resistance of microorganisms to antibiotics, including carbapenems, which until recently were considered as the drugs of choice in the treatment of life-threatening infections.
Popov D.A., Zubareva N.A., Parshakov A.A.   +2 more
doaj   +1 more source

Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant Klebsiella pneumoniae: A Retrospective Case Series and Literature Review

Antibiotics, 2022
Objectives: The aim of this study was to describe our experience of a combination treatment including meropenem/vaborbactam (M/V) plus aztreonam (ATM) for bloodstream infections (BSIs) due to ceftazidime/avibactam-resistant Klebsiella pneumoniae (CAZ/AVI-
Alessandra Belati, Davide Fiore Bavaro, Lucia Diella, Nicolò De Gennaro, Francesco Di Gennaro, Annalisa Saracino   +5 more
doaj   +1 more source

Direct Detection of Extended Spectrum β-Lactamases from Positive Blood Cultures by using Aztreonam and Clavulanate [PDF]

Journal of Clinical and Diagnostic Research, 2021
Introduction: Bacterial Sepsis by Multidrug Resistant Gram Negative Bacilli (MDRGNB) producing Extended Spectrum β-Lactamases (ESBL) is one of the major causes of mortality and morbidity in hospitals.
Renji Francis, Ambica Rangaiah, Kusuma Gowdra Rangappa, Shwetha Jinnahalli Venugopal   +3 more
doaj   +1 more source

In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing Enterobacter cloacae and Klebsiella pneumoniae in Murine Pneumonia Model

Antibiotics, 2021
Carbapenem-resistant Enterobacterales (CRE) and carbapenemase-producing Enterobacterales (CPE) have become global threats. CRE− and CPE− derived infections have been associated with high mortality due to limited treatment options.
Mao Hagihara, Hideo Kato, Toshie Sugano, Hayato Okade, Nobuo Sato, Yuichi Shibata, Daisuke Sakanashi, Jun Hirai, Nobuhiro Asai, Hiroyuki Suematsu, Yuka Yamagishi, Hiroshige Mikamo   +11 more
doaj   +1 more source

Antimicrobial therapy of sepsis caused by carbapenem-resistant Klebsiella pneumoniae in patients with hematological malignancies [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2022
Objective. To compare the efficacy of ceftazidime-avibactam and aztreonam combination therapy with “standard” therapy in patients with hematological malignancies and sepsis, caused by carbapenemresistant K. pneumoniae. Materials and Methods.
Barantsevich N.E., Barantsevich E.P.
doaj   +1 more source

Synthesis and penicillin‐binding protein inhibitory assessment of dipeptidic 4‐phenyl‐β‐lactams from α‐amino acid‐derived imines [PDF]

, 2020
Monocyclic beta-lactams revive the research field on antibiotics, which are threatened by the emergence of resistant bacteria. A six-step synthetic route was developed, providing easy access to new 3-amino-1-carboxymethyl-4-phenyl-beta-lactams, of which ...
Amoroso, Ana Maria, D'hooghe, Matthias, Decuyper, Lena, Gobec, Stanislav, Joris, Bernard, Jukič, Marko, Sosič, Izidor, Verlaine, Olivier   +7 more
core   +2 more sources

Assessment of Safety Signals for Aztreonam in Different Age Groups: National and International Drug Safety Monitoring

Безопасность и риск фармакотерапии, 2022
Aztreonam is the only approved monocyclic β-lactam antibiotic for human use that is active against Gram-negative aerobes, primarily Pseudomonas аeruginosa. Aztreonam has been used for more than 35 years, and aztreonam lysine has been on the market for 15
E. A. Sokova, V. V. Arkhipov, A. S. Kazakov, B. K. Romanov, R. N. Alyautdin, M. V. Zhuravleva   +5 more
doaj   +1 more source

Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections [PDF]

, 1986
The minimal inhibitory concentrations (MICs) of aztreonam and cefotaxime were determined against 400 isolates from urological in-patients with complicated and/or hospital acquired urinary tract infections (UTI).
Dette, G. A., Grobecker, H., Kees, Frieder K., Knothe, H., Naber, K. G.   +4 more
core   +1 more source